Equitable access to vaccines, tests and treatments for Covid-19

Listing summary

Any Covid-19 vaccines, tests and treatments developed should benefit the whole world. We are working with the ACT-Accelerator and other international partners to make sure that happens.

Priority areas
English
Standfirst

Any Covid-19 vaccines, tests and treatments developed should benefit the whole world. We are working with the ACT-Accelerator and other international partners to make sure that happens.

Display live chat
Off
Content
Group title
What equitable access means
Admin title
What equitable access means
Group
Body

Equitable access to Covid-19 tests, treatments and vaccines means that:

  • they are available everywhere, regardless of where they have been developed or who funded them
  • appropriate options exist for all healthcare settings, whether in low- or high-income countries
  • safe and effective options reach all groups of people, regardless of race, age or other demographics
  • they are affordable to poor and rich countries alike, not only to those who can pay the most.

People who are most at risk of getting infected with coronavirus or getting severely ill need tests, treatments and vaccines the most, and should get access first. These include healthcare workers, the elderly and people with co-morbidities, and people that are unable to practice social distancing and regular handwashing, for example if they live in overcrowded refugee camps or who have limited access to running water.  

Group title
Why global equitable access is important
Admin title
Why global equitable access is important
Group
Body

No one is protected against Covid-19 unless everyone is.

Equitable access to Covid-19 tests, treatments and vaccines in all countries will lead to the pandemic ending sooner, many lives saved, a return of international mobility and trade, and a start to economic recovery.

The $28.1 billion investment still needed to develop these lifesaving tools could be recouped in 36 hours once international mobility and trade are restored.

This investment is less than 1% of what G20 countries have already unlocked to support businesses and national economies.

Image
Graphic showing the size of the stimulus packages unlocked by ten G20 countries.
File size
154214 bytes
Image width
2500px
Image height
1309px
Filename
covid-social-economic-impacts-investment-stimulus_1.png
Image
Graphic showing the size of the stimulus packages unlocked by ten G20 countries.
Download allowed
On
Body

It is in every country’s best interest to work together to bring the pandemic to an end. Global solidarity – and global investment – are essential.

This is also what the public wants. Wellcome polling of more than 6,000 adults in the UK, the USA, Germany and France shows strong public support for making sure that any new coronavirus treatments and vaccines are first made available to those who need them most.

Admin title
Quote
Group title
What you can do
Admin title
What you can do
Group
Body

Governments, international financing institutes, the private sector and philanthropies must invest in research and development of Covid-19 tools, and make sure they are distributed fairly.  

There are three main things they can do.

1. Invest in the Access to COVID-19 Tools (ACT) Accelerator

This is a ground-breaking global collaboration that brings together governments, scientists, businesses, civil society, philanthropists and international health organisations. It needs a total investment of $33.2 billion to help provide:

  • 2 billion vaccine doses globally by the end of 2021
  • 245 million treatment courses in low- and middle-income countries by mid-2021
  • 500 million tests in low- and middle-income countries by mid-2021.

The ACT-Accelerator is an end-to-end global solution to the Covid-19 pandemic. It aims to develop, scale and enable equitable global access to tests, treatments and vaccines, and so far has the largest portfolio of Covid-19 tools in the world.

By investing in the ACT-Accelerator, governments will have a better chance of accessing the successful tools.

2. Commit to and take action to ensure equitable access

Once new treatments, tests and vaccines are licensed and approved, supplies will be limited. Governments should not buy or hoard more than they need, to make sure that these lifesaving tools are available and affordable to all countries.

Governments and pharmaceutical companies should be transparent about any bilateral deals they make – particularly about if and how those deals will support access in low- and middle-income countries.

Recognising the severity of this crisis, some companies have already committed to providing vaccine doses on a non-profit basis during the pandemic. Other companies producing vaccines, treatments and diagnostics should follow this example where possible and, at minimum, negotiate pricing mechanisms that guarantee affordable doses to all those affected, regardless of their ability to pay. This may require donor support to ensure affordability.

3. Follow the WHO allocation framework

The World Health Organization (WHO) is developing principles, frameworks and mechanisms to make sure that there is equitable allocation of Covid-19 tools.

Governments should follow these when planning, buying and delivering vaccines, treatments and tests.

Group title
Where the investment is needed
Admin title
Where the investment is needed
Group
Body

The total investment needed for the ACT-Accelerator is $33.2 billion. This will cover:

  • Vaccines: $11.1 billion for CEPI, the Coalition for Epidemic Preparedness Innovations, and GAVI, the Vaccine Alliance, of which $1 billion is needed immediately
  • Therapeutics: $6.6 billion for the Therapeutics Accelerator and Unitaid, of which $750 million is needed immediately
  • Diagnostics: $6 billion for FIND, the Foundation for Innovative New Diagnostics, and the Global Fund, of which $1.1 billion is needed immediately
  • Health systems: $9.5 billion for the World Bank, the WHO and the Global Fund, of which $1.7 billion is needed immediately.

So far, only $5.1 billion has been pledged, leaving a gap of $28.1 billion. The Economist Intelligence Unit’s COVID-19 Health Funding Tracker is tracking money pledged and disbursed to the ACT-Accelerator partners.

Image
Graphic showing how much money has been pledged of the total investment needed for Covid-19 treatments, vaccines, tests and health systmes.
File size
757633 bytes
Image width
2500px
Image height
1308px
Filename
equitable-access-infographic-funding.jpg
Image
Graphic showing how much money has been pledged of the total investment needed for Covid-19 treatments, vaccines, tests and health systmes.
Download allowed
On
Group title
Related content
Admin title
Related content
Group
Admin title
Related content
Listing layout
Image card with CTA link (Horizontal card)
Content
Body
[Summary] Our polling of more than 6,000 adults in the UK, the USA, Germany and France shows strong public support for making sure that any new coronavirus treatments and vaccines are first made available to those who need them most.
Title
What people think about global access to COVID-19 treatments and vaccines
Published date
Modified date
Admin title
Related content
Image
Graphic showing two men wearing masks and a pill
File size
149028 bytes
Image width
512px
Image height
288px
Filename
coronavirus-treatments-and-vaccines-promo.jpg
Image
Graphic showing two men wearing masks and a pill
Download allowed
On
Body
We’ve awarded £12 million, in partnership with DFID, to speed up global COVID-19 research and development and help low- and middle-income countries prepare. But more investment is needed.
Title
Greater investment is needed to help countries with the weakest health systems prepare for COVID-19
Content type
Opinion
Published date
Modified date
Author
Christiane Hertz-Fowler and Georgia Walton
Admin title
Related content
Image
Five parishoners in Malawi wash their hands as a preventive measure against the spread of COVID-19
Credit
Amos Gumulira / AFP / Getty Images
Caption

Parishoners in Malawi wash their hands as a preventive measure against the spread of Covid-19.

File size
1583484 bytes
Image width
1200px
Image height
675px
Filename
greater-investment-needed-to-help-countries-with-weakest-health-systems-prepare-for-covid-19-150420-1200.png
Image
Five parishoners in Malawi wash their hands as a preventive measure against the spread of COVID-19
Download allowed
On
Body
We want to help the world overcome Covid-19. Research is the best way to save lives – but more investment in accessible treatments, tests and vaccines is urgently needed to change the course of the pandemic.
Title
Coronavirus (Covid-19): supporting global research and development
Published date
Modified date
Admin title
Related content
Image
A map of the world, a hand holding a test tube and three children washing their hands
File size
866480 bytes
Image width
3333px
Image height
1204px
Filename
coronavirus-covid-19-supporting-global-research-and-development-1600px_0.jpg
Image
A map of the world, a hand holding a test tube and three children washing their hands
Download allowed
On
Ordering date
Meta title
Coronavirus (COVID-19): equitable access | Wellcome
Published on
Meta description
Wellcome is calling on all R&D funders, developers and manufacturers to help ensure that new vaccines, diagnostics and treatments developed for COVID-19 are globally available, appropriate and affordable.
Banner styling
Banner with image above title
Exclude from listings
Off
Add noindex
Off
Display sibling navigation menu
Off